Johnson & Johnson (NYSE: JNJ) today announced that the District of Massachusetts Federal Court has issued a ruling on a summary judgment motion filed by Celltrion Healthcare Co. Ltd. and Celltrion Inc
FDA action marks second Breakthrough Therapy Designation for intranasal esketamine, highlighting its potential as treatment for patients with major depressive disorder who are at imminent risk for ...
The Johnson & Johnson Medical Devices Companies are helping health systems across the US achieve better outcomes, efficiencies and higher patient satisfaction through its proven DePuy Synthes ...
In a development that further underscores ways in which medical devices are being personalized for individual patients, DePuy Synthes, part of the Johnson & Johnson family of companies, announced an ...